Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients

Conclusions: Overall, monoclonal antibodies are reasonably well-tolerated COVID-19 therapies in high-risk adolescent and young adult populations.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: COVID Reports Source Type: research